X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences
Rhea-AI Summary
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on rare immune system diseases, has announced its participation in three major investor conferences in September 2024. These include:
- Morgan Stanley 22nd Annual Global Healthcare Conference on September 4
- Wells Fargo Healthcare Conference on September 5
- Cantor Fitzgerald Global Healthcare Conference on September 17
The company will engage in fireside chats and one-on-one meetings at these events. Live webcasts for the Morgan Stanley and Cantor Fitzgerald conferences will be available on X4's website, with replays accessible afterwards. Investors interested in one-on-one meetings should contact their respective conference representatives.
Positive
- None.
Negative
- None.
News Market Reaction – XFOR
In the trading session that priced this news, XFOR declined 1.43%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in three upcoming investor conferences in September 2024:
Morgan Stanley 22nd Annual Global Healthcare Conference
Date: Wednesday, September 4, 2024
Time: 2:35 PM EDT
Format: Fireside Chat and 1x1 Meetings
Webcast Link
Wells Fargo Healthcare Conference
Date: Thursday, September 5, 2024
Format: 1x1 Meetings
Cantor Fitzgerald Global Healthcare Conference
Date: Tuesday, September 17, 2024
Time: 3:40 PM EDT
Format: Fireside Chat and 1x1 Meetings
Webcast Link
The live webcasts for the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Fitzgerald Global Healthcare Conference will also be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the completion of these fireside chats, the webcast replays will be available on the X4 website.
For interested investors looking to schedule one-on-one meetings with company management, please contact your respective Morgan Stanley, Wells Fargo, or Cantor Fitzgerald representatives.
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI™ (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
